Gene therapy can partly restore sight in blind people, researchers reveal

A novel gene therapy utilizing Nobel prize-winning science has been shown to safely and partly restore sight in blind individuals, according to research published in the New England Journal of Medicine. Known as optogenetic therapy, the approach harnesses techniques for turning nerve cells on and off using light — science that recently scooped the 2026 Nobel prize in physiology or medicine. Following an initial proof-of-concept trial in a single patient first reported in 2021, an international research team has now revealed results from a larger trial involving that original participant and a further nine people.

The collaborative effort was led by Dr. José-Alain Sahel from the University of Pittsburgh Medical Center in the United States and Prof. Botond Roska, director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) in Switzerland. The clinical cohort also involved GenSight Biologics alongside other international researchers. IOB operates as a foundation with founding partners including the University Hospital Basel, the University of Basel, and Novartis, with substantial financial support from the Canton of Basel-Stadt.

Understanding Retinitis Pigmentosa and the Optogenetic Approach

All participants in the trial suffered from advanced retinitis pigmentosa, a group of genetic disorders affecting more than 1.5 million people worldwide. In these conditions, the light-sensitive photoreceptor cells in the retina gradually degenerate and lose their ability to respond to light. Pinning down an exact treatment has proven exceptionally challenging because mutations in more than 100 different genes can cause the disease. Conventional strategies such as gene editing or gene replacement require targeting specific genetic defects, making separate treatments for every mutation tremendously difficult and costly.

Optogenetic therapy bypasses this genetic barrier entirely. While photoreceptors degrade, ganglion cells in the retina — which transmit visual information onward to the brain, deteriorate much less quickly. Because these ganglion cells are not the primary targets of the disease, they serve as ideal candidates for intervention. The therapy involves a single intraocular injection into the patient's worse-seeing eye. This injection delivers a harmless, synthetic viral vector carrying genetic instructions to produce ChrimsonR, a light-sensitive protein that responds to amber light. As a result, a ring of surviving ganglion cells acquires light sensitivity.

Trial Metric	Patient Outcome / Observation
Total Trial Participants	10 adults with advanced retinitis pigmentosa
Primary Endpoint	Safety (demonstrated mostly mild-to-moderate, temporary adverse events)
Light Sensitivity Improvement	6 of 10 participants reached clinically meaningful thresholds
Visual Behavioral Testing	Patients improved in tasks such as detecting objects, locating doorways, and following lines
Follow-up Duration	Monitored for up to five years post-treatment

Safety, Efficacy, and the Role of Rehabilitation

Safety served as the primary endpoint for the trial, and the intervention was deemed safe within the study limits. Most eye-related adverse events were mild or moderate, though inflammation occurred more frequently in patients receiving higher doses. One severe eye-related side effect happened immediately following injection, but it resolved within minutes. No side effects related to the therapy manifested in the rest of the body.

Beyond safety, the results showed measurable functional gains. Six of the 10 participants achieved clinically meaningful improvements in light sensitivity in their treated eyes. Patients were equipped with specialized goggles featuring a built-in camera that captures visual scenes and converts them into pulses of amber light matching the sensitivity of the modified ganglion cells. Measurements of brain activity confirmed signals reaching the visual areas of the brain.

While the treatment does not restore normal vision, patients remain unable to read or recognize faces because the treated ganglion cells sit in a ring-like arrangement around the fovea, participants demonstrated tangible behavioral improvements. When wearing the goggles, several individuals successfully detected, located, and touched a notebook, located a doorway, or followed a line marking a route. Researchers emphasized that training played a crucial role in these outcomes, with patients who spent more time learning to use the goggles performing better on tasks.

Expert Perspectives and Future Outlook

Independent experts welcomed the expanded data. Prof. Mark Hankins of Visual Neuroscience at the University of Oxford, who was not involved in the work, noted that the study provides vital reassurance regarding safety and stability.

"We’ve gone from one patient to 10 patients, we’ve seen improvement in their light sensitivity … and we’ve seen that we can give a stable restoration of some visual function, some light sensitivity, that lasts for four or five years in these patients. They’re baby steps, but they’re critical."

Mark Hankins, Professor of Visual Neuroscience at the University of Oxford, via The Guardian

Stefan Futterknecht, second author of the study and data analyst, stated that the findings confirm initial observations can be reproduced across multiple patients, establishing a solid foundation for more sensitive treatments. Meanwhile, Sahel highlighted the remarkable plasticity of the visual system even amid profound vision loss. Researchers noted that applying optogenetic interventions earlier in the disease progression, when more retinal cells remain intact, could potentially yield even more transformative results.

The convergence of the trial data with the recent Nobel Prize recognition has energized the scientific team. Sahel noted that the Nobel Committee explicitly referenced clinical demonstrations in vision restoration, providing fresh encouragement to optimize future iterations of the technology. Moving forward, the collaborative team aims to push toward achieving high-resolution vision, projecting that goal within the next five to ten years.